Testing XNW5004 with other drugs for advanced prostate cancer
Treatments studied
Part of Cancer clinical trials.
This study tests a new oral drug called XNW5004 in combination with other standard treatments (like abiraterone, enzalutamide, or chemotherapy) for advanced prostate cancer that has spread and is no longer controlled by hormone therapy alone. The goal is to see if these combinations work better than current options.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are male and at least 18 years old.
- Your prostate cancer has spread to bones or soft tissues (like lymph nodes) and can be seen on scans.
- You are currently on hormone therapy to lower testosterone (or have had your testicles removed) and your testosterone level is very low.
- Your cancer has gotten worse while on hormone therapy—shown by rising PSA, new growth on scans, or new bone lesions.
- Your prior treatment history fits one of the study groups: for example, you have taken a newer hormone therapy (like enzalutamide) but not abiraterone, and it stopped working, OR you have not had any cancer treatment besides hormone therapy and maybe a first-generation antiandrogen (like bicalutamide).
- You are generally healthy enough for daily activities and have adequate organ function (liver, kidneys, blood counts).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two new drugs (QLC5508 and QLH12016) alone or together with other treatments for prostate cancer that has spread to other parts of the body. It may be an option if standard treatments have stopped working or caused side effects.
This trial tests a new drug, XNW5004, combined with enzalutamide for men with metastatic castration-resistant prostate cancer that has progressed despite other treatments. It aims to see if this combination can slow the cancer's growth.
This trial tests a new drug called XNW34017 for people with advanced solid tumors, including small cell lung cancer and prostate cancer. It may be an option if you've tried other treatments that no longer work.
This trial tests a new combination of two study drugs for people with advanced prostate cancer that has spread or is no longer responding to hormone therapy. The goal is to see if the combination is safe and works against the cancer.
This trial tests a new combination of two drugs (xaluritamig plus abiraterone) for men with a type of advanced prostate cancer that is no longer responding to hormone therapy but has not yet been treated with chemotherapy. The goal is to see if this combination works better than the standard options your doctor might choose.
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
Hear when a new Advanced Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.